Purpose: The influence of dyslipidemia on long-term aneurysmal sac behaviour following endovascular aortic repair (EVAR) remains uncertain. This study examined whether dyslipidemia affects sac regression or clinical outcomes in patients treated with the GORE® EXCLUDER® endoprosthesis. Methodology: We conducted a retrospective analysis of 3,453 patients with infrarenal abdominal aortic aneurysms from a multinational registry (2014–2016), encompassing centres across Europe, the Americas, Australia, and New Zealand. All patients underwent elective EVAR and completed 6-year imaging follow-up. Patients were stratified by dyslipidemia status and matched 1:1 using propensity scores to adjust for baseline differences. The primary endpoint was sac regression; secondary endpoints included mortality, endoleaks, and reinterventions. Results: After matching, 2,269 patients with dyslipidemia were compared to an equal number without. Sac regression at 1 year (p=0.70) and at 6 years (p=0.14) did not significantly differ. Endoleak and reintervention rates were similarly low in both groups throughout follow-up. Notably, all-cause mortality was significantly lower in the dyslipidemia group (6.7% vs. 10.6%; p=0.018), while aortic-related mortality was comparable (p=0.662). Within the dyslipidemia cohort, increased aneurysm diameter at 1 year (p=0.037) and older age at 6 years (p<0.001) were associated with sac expansion. Patients without dyslipidemia were more often treated off-label (p=0.030) and had shorter aneurysm necks (p=0.035), potentially contributing to their higher mortality. Conclusions: Dyslipidemia was not associated with inferior sac regression or procedural outcomes following EVAR. The lower all-cause mortality among dyslipidemic patients may reflect greater use of cardiovascular preventive therapies. These findings support the long-term safety and efficacy of EVAR in patients with dyslipidemia.